Enter assignee name

EPO Patents = 5

Forward Citations = 125

Loading Chart...

7 inventors (with patents filed for the assignee):

Jamey Paul Weichert (12 out of 45 patents)

Marc Longino (12 out of 20 patents)

Anatoly Pinchuk (10 out of 30 patents)

4. Irawati Kandela (4 out of 5 patents)

5. William R Clarke (4 out of 7 patents)

6. Sharon Weber (1 out of 1 patent)

7. Joseph O Nwankwo (1 out of 1 patent)

12 patents: Sort by Forward Citations

1. 10004818 - Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer (2018-06-26),

2. 9339564 - Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer (2016-05-17),

3. 8877160 - Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof (2014-11-04),

4. 8877159 - Phospholipid analogs as diapeutic agents and methods thereof (2014-11-04),

5. 8871181 - Fluorescent phospholipid ether compounds, compositions, and methods of use (2014-10-28),

6. 8540968 - Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof (2013-09-24),

7. 8535641 - Phospholipid analogs as diapeutic* agents and methods thereof (2013-09-17),

8. 8022235 - Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use (2011-09-20),

9. 7893286 - Method for the synthesis of phospholipid ethers (2011-02-22),

10. 7811548 - Fluorescent phospholipid ether compounds and compositions (2010-10-12),

11. 7700075 - Virtual colonoscopy with radiolabeled phospholipid ether analogs (2010-04-20),

12. 7632644 - Imaging and selective retention of phospholipid ether analogs (2009-12-15),

Cellectar, Inc. is a biotechnology company based in Madison, Wisconsin, specializing in the development of innovative therapies for cancer treatment. The company focuses on its proprietary phospholipid drug conjugate (PDC) platform, which aims to enhance the delivery of therapeutic agents directly to cancer cells while minimizing effects on healthy tissues. Cellectar's research encompasses targeted therapies designed to address various types of cancer, leveraging advanced drug delivery mechanisms to improve patient outcomes.

Profile summary based on public USPTO records.